Tagged with Innovation

Brazil Rolf Hoenger, president and general manager of Roche Pharma Brazil, provides an inspiring insight into the innovative and multi-faceted market access vision implemented by the Brazilian affiliate under his tenure and documents his personal approach to bolstering creativity at the affiliate level and ultimately fulfill the company’s fundamental objective to…

Brazil Bruno Costa Gabriel, managing director of Janssen Brazil, provides insights into the transformative market approach successfully implemented by this leading company in Brazil and his main priorities to further leverage the great potential of Janssen’s innovation and impact an ever-increasing number of Brazilian patients.   You display a truly international…

Brazil Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years and details Sanofi’s strategy in Brazil; a ‘must-win’ market for the company. Unsatisfied with being just the top-ranked multinational pharma company in Brazil, he…

Canada Quebec’s Deputy Premier and Minister of Economy, Science and Innovation Dominique Anglade, who is also the Minister responsible for the Digital Strategy, shares the strategic significance of her portfolios to Quebec’s national development, the CAD 205 million Quebec is investing into the life sciences sectors over the next five years,…

Japan Yuzo Toda, chairman of the Forum for Innovative Regenerative Medicine (FIRM) in Japan, discusses how the organization acts as a translational bridge between academia and industry, how the paradigm of regenerative medicine differs from that of traditional pharmaceuticals, and why Japan has taken the lead in this exciting new field.…

Japan Dr. Tatsuya Kondo is chief executive of Japan’s regulatory authority, the Pharmaceuticals and Medical Devices Agency (PMDA). Since taking the role in 2008, Dr. Kondo, a qualified neurosurgeon with wide-ranging experience in R&D activities, has been responsible for all the operations of PMDA, including relief for adverse health effects of…

Canada Michel Lavoie, president & CEO of Dermtek Pharma in Canada, discusses the family-owned company’s track record of success over the past three decades, the emphasis they place on R&D and product development, with successful brands like Ombrelle and Reversa, and his commitment to growing Dermtek Pharma as a truly Canadian,…

Lithuania Rūta Pumputienė, head of the Local American Working Group (LAWG), explains the main dynamics impacting the pharmaceutical sector in general as well as the key role of the LAWG in supporting the better access to innovative treatments. Can you please introduce yourself to our international audience as well as the…

Canada Dr. Reza Moridi, Minister of Research, Innovation and Science of the province of Ontario presents the impressive scope of investments undertaken within the fields of innovation and life sciences in particular over recent years. The already impressive scope of excellence in Ontario’s hospital, research and innovation, and investment landscape will…

Brazil Neide Kawabata, president of B Braun Brazil, shares B Braun’s long track record of success and commitment to Brazil, the innovations they continue to bring to the market, and the long-term vision and community support B Braun brings to its affiliates globally, as a sixth-generation family-owned company. Neide, could you…

Canada Greig Estabrooks, general manager of Valneva, talks partnership opportunities for the French-Austrian pure-play vaccine company in Canada, its exciting pipeline, and how he encourages his global R&D colleagues to consider conducting clinical trials for their pipeline products in Canada in order to leverage the country’s great infrastructure and significant human…

Brazil Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for Brazilians, and the company’s current research on immunostimulants. Before presenting the company, could you tell our readers what motivated you…